DISSAL - Section of Dermatology, University of Genoa, Genoa, Italy.
San Martino IRCCS Polyclinic Hospital, Genoa, Italy.
Int J Dermatol. 2023 Jul;62(7):847-849. doi: 10.1111/ijd.16695. Epub 2023 Apr 26.
Since vaccines against COVID-19 are available, it has been debated if immunosuppressed patients with autoimmune blistering diseases (AIBDs) should be advised to interrupt the immunosuppressive therapy before receiving the vaccine, with consequent risk to experience a flare of disease. In the present study, we measured the neutralizing antibodies production after anti-SARS-CoV-2 vaccination in patients with AIBDs on immunosuppressive treatment, compared to healthy controls. Our results give strength to the hypothesis that these patients do not need to discontinue their therapy to produce effective levels of neutralizing antibodies, in other words to achieve successful protection.
由于 COVID-19 疫苗已经问世，因此一直存在争议，即是否应该建议接受自身免疫性水疱性疾病（AIBD）的免疫抑制患者在接种疫苗之前中断免疫抑制治疗，从而导致疾病复发的风险。在本研究中，我们测量了接受免疫抑制治疗的 AIBD 患者接种抗 SARS-CoV-2 疫苗后的中和抗体产生情况，并与健康对照组进行了比较。我们的结果支持以下假设，即这些患者无需停止治疗即可产生有效的中和抗体水平，换句话说，可实现成功的保护。
